Imaging and interoperability solutions provider, Merge Healthcare ( MRGE ) announced another addition to its ever-increasing client list with the latest deal with Datapharm Australia Pty
GlaxoSmithKline ( GSK ) recently presented positive data on its oncology drug, Votrient (pazopanib) from a pivotal phase III study. The phase III study COMPARZ (COMParing the efficacy,
We downgrade our recommendation for Conmed Corporation ( CNMD ) to ‘Underperform’, driven by difficult hospital capital equipment spending environment and management’s lowered sales